

Special Issue

Neutralizing Antibodies after SARS-CoV-2 Vaccination

Message from the Guest Editors

COVID-19, caused by the SARS-CoV-2-virus, has placed a significant burden on healthcare systems and societies around the world. The approval of several vaccines has alleviated the global situation, forming a core element in the fight against the pandemic. To further develop an ongoing vaccination protocol, including so-called booster vaccinations after primary immunization, reliable parameters are needed. The overall antibody response after infection or vaccination has been intensively studied. However, the role of neutralizing antibodies is still poorly understood, as their use is limited to highly specialized laboratories. The implementation of enzyme-linked immunosorbent assay (ELISA)-based surrogate virus neutralization tests (sVNTs), as well as cell-culture-based virus neutralization assays, could help us to gain a better understanding of these functional antibodies. Therefore, this Special Issue “Neutralizing Antibodies after SARS-CoV-2 Vaccination” of *Vaccines* aims to focus on studies that report results of neutralizing antibodies after SARS-CoV-2 vaccination.

Guest Editors

Prof. Dr. Tanja Vollmer

Dr. Jonas Herzberg

Dr. Bastian Fischer

Deadline for manuscript submissions

closed (29 February 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/170144

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).